Novo Nordisk A/S (NOV.DE)

EUR 58.11

(-0.92%)

EBITDA Summary of Novo Nordisk A/S

  • Novo Nordisk A/S's latest annual EBITDA in 2023 was 114.62 Billion DKK , up 37.5% from previous year.
  • Novo Nordisk A/S's latest quarterly EBITDA in 2024 Q2 was 35.73 Billion DKK , up 1.16% from previous quarter.
  • Novo Nordisk A/S reported an annual EBITDA of 76.8 Billion DKK in 2022, up 25.61% from previous year.
  • Novo Nordisk A/S reported an annual EBITDA of 65.39 Billion DKK in 2021, up 8.37% from previous year.
  • Novo Nordisk A/S reported a quarterly EBITDA of 4.72 Billion DKK for 2024 Q1, up 15.41% from previous quarter.
  • Novo Nordisk A/S reported a quarterly EBITDA of N/A for 2023 FY, up 37.5% from previous quarter.

Annual EBITDA Chart of Novo Nordisk A/S (2023 - 2016)

Historical Annual EBITDA of Novo Nordisk A/S (2023 - 2016)

Year EBITDA EBITDA Growth
2023 114.62 Billion DKK 37.5%
2022 76.8 Billion DKK 25.61%
2021 65.39 Billion DKK 8.37%
2020 59.27 Billion DKK 3.28%
2019 54.43 Billion EUR 15.3%
2018 51.62 Billion EUR -2.37%
2017 51.95 Billion EUR 0.32%
2016 51.05 Billion EUR 0.0%

Peer EBITDA Comparison of Novo Nordisk A/S

Name EBITDA EBITDA Difference
BioNTech SE 1.08 Billion EUR -10439.629%
CureVac N.V. -234.09 Million EUR 49067.918%
Biotest Aktiengesellschaft 179 Million EUR -63938.547%
Biotest Aktiengesellschaft 179 Million EUR -63938.547%
BRAIN Biotech AG -2.38 Million EUR 4802320.36%
Formycon AG 81.05 Million EUR -141324.749%
Heidelberg Pharma AG -18.7 Million EUR 612880.37%
Medigene AG -14.58 Million EUR 786037.661%